The DOI matches its Crossref record.
Phase II Evaluation of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: A Japanese Esophageal Oncology Group Trial
Abstract
Thirty-nine patients with advanced measurable squamous cell carcinomas were treated with two or more courses of 70 mg cisplatin/m2 on day 1 and 700 mg infused 5-fluorouracil/m2 on days 1-5 every 21 days. The overall response rate was 35.9 (95% confidence limits, 24.8-55.1%). Responses were seen in primary sites in the esophagus of five patients, in the lung of seven, the liver of one and the mediastinal lymph nodes of one. The average response duration was 3.5 (range 1-12) mo for patients who achieved partial response. The average survival time after the first administration was 9.5 mo for patients who responded to the treatment whereas, for those who did not, it was 5.6 mo. The major form of toxicity was myelosuppression and there were six patients with grade 3 toxicity and one with grade 4. The present study was designed to evaluate the effectiveness of combined cisplatin and 5-fluorouracil for advanced squamous cell carcinoma, and the results showed that it had a reasonable effect and might possibly be used as a postoperative chemotherapy because of its mild side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Doki, Y., Ajani, J. A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C.-H., Adenis, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111380 · Cited by 1,230
Ando, N., Iizuka, T., Ide, H., Ishida, K., Shinoda, M., Nishimaki, T., Takiyama, W., Watanabe, H., Isono, K., Aoyama, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.095 · Cited by 722
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Kitagawa, Y., Uno, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawamura, O., Kusano, M., Kuwano, H., Takeuchi, H., et al. (2019) · Esophagus · doi:10.1007/s10388-018-0642-8 · Cited by 569
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Kitagawa, Y., Uno, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawamura, O., Kusano, M., Kuwano, H., Takeuchi, H., et al. (2019) · Esophagus · doi:10.1007/s10388-018-0641-9 · Cited by 519
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1
Kitagawa, Y., Ishihara, R., Ishikawa, H., Ito, Y., Oyama, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawachi, H., et al. (2023) · Esophagus · doi:10.1007/s10388-023-00993-2 · Cited by 427
Metadata
- Venue
- Japanese Journal of Clinical Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-06
- Volume
- 22
- Issue
- 3
- Pages
- 172-6
- ISSN
- 0368-2811 (ISSN-L)
- 1465-3621
- OpenAlex
- W1878554291
- Cited by
- 209
- References
- 0
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Evaluation of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: A Japanese Esophageal Oncology Group Trial. https://app.cochat.ai/papers/10.1093/oxfordjournals.jjco.a039543
- The paper
- Phase II Evaluation of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: A Japanese Esophageal Oncology Group Trial. (1992). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/oxfordjournals.jjco.a039543
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.